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Abstract  34 
Although defects in the RB1 tumour suppressor are one of the more common 35 
driver alterations found in triple negative breast cancer (TNBC), therapeutic 36 
approaches that exploit this have not been identified. By integrating molecular 37 
profiling data with data from multiple genetic perturbation screens, we 38 
identified candidate synthetic lethal (SL) interactions associated with RB1 39 
defects in TNBC. We refined this analysis by identifying the highly penetrant 40 
effects, reasoning that these would be more robust in the face of molecular 41 
heterogeneity and would represent more promising therapeutic targets. A 42 
significant proportion of the highly penetrant RB1 SL effects involved proteins 43 
closely associated with RB1 function, suggesting that this might be a defining 44 
characteristic. These included nuclear pore complex components associated 45 
with the MAD2 spindle checkpoint protein, the kinase and bromodomain 46 
containing transcription factor TAF1 and multiple components of the SCFSKP 47 
Cullin F box containing complex. Small molecule inhibition of SCFSKP elicited 48 
an increase in p27Kip levels, providing a mechanistic rationale for RB1 SL. 49 
Transcript expression of SKP2, a SCFSKP component, was elevated in RB1 50 
defective TNBCs, suggesting that in these tumours, SKP2 activity might buffer 51 
the effects of RB1 dysfunction.  52 
  53 
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Introduction 58 
Patients who develop triple negative breast cancer (TNBC), i.e. those breast 59 
cancers that lack amplification of the ERBB2 gene as well as expression of 60 
both the estrogen and progesterone receptors, tend to have a relatively poor 61 
prognosis and represent a significant area of unmet clinical need, where novel 62 
therapeutic approaches are acutely needed (recently reviewed in 5). Although 63 
some targeted approaches have been proposed for molecularly defined 64 
subsets of TNBC patients, for most, classical chemotherapy regimens still 65 
represent the mainstay of treatment, making the requirement to identify novel 66 
targets in this disease critical. One approach to this problem has been to 67 
define the molecular composition of TNBCs and then to use this information to 68 
help identify therapeutic vulnerabilities that might operate in the disease. 69 
Already, the delineation of genomic, transcriptomic and proteomic profiles of 70 
tumours has identified a series of distinct molecular subtypes of TNBC, as 71 
well as identifying likely cancer driver gene mutations that operate in the 72 
disease51. 73 
 74 
One of the more frequent driver alterations in TNBCs involves deleterious 75 
mutations (e.g. truncating mutation, gene deletions etc.) in the 76 
Retinoblastoma tumour suppressor gene (RB1 aka Rb). In non-tumour cells, 77 
Rb’s canonical role is in cell cycle progression, a function mediated in part by 78 
the repressive effect Rb has on the E2F family of transcription factors29. A 79 
somewhat reductionist model of Rb’s role in tumour suppression, suggests 80 
that loss of Rb’s E2F repressive function allows cells to prematurely transition 81 
through the G1 cell cycle checkpoint; it also seems likely that loss of Rb 82 
function in breast cancer also influences additional processes that contribute 83 
to the development of the disease including the differentiation of stem and 84 
progenitor cells and the transition of cells from an epithelial to a mesenchymal 85 
phenotype29. 86 
 87 
Commensurate with its key role in cell cycle control, genomic alterations in the 88 
RB1 gene are relatively common in TNBCs31, 32, 49 as well as in a series of 89 
other malignancies17, 27, 60. In TNBC, loss of Rb protein expression is found in 90 
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> 40 % of cases58, 61 (and reviewed in30). Although patients with Rb defective 91 
tumours (as defined by immunohistochemistry and/or gene expression) tend 92 
to have a relatively favorable response to classical chemotherapy20, 26, 64 93 
many either fail to respond to therapy or later relapse with therapy resistant 94 
disease, suggesting that novel therapeutic approaches are required to target 95 
this patient subset.  96 
 97 
One approach to identifying novel therapeutic targets that could be exploited 98 
in patients with specific tumour suppressor gene defects has been to identify 99 
synthetic lethal interactions associated with these genes. For example, the 100 
identification of synthetic lethal interactions between BRCA1 or BRCA2 101 
tumour suppressor genes and inhibition of the PARP1 DNA repair protein, has 102 
driven the clinical development and approval for use of PARP inhibitors for the 103 
treatment of cancer39. One notable feature of the BRCA/PARP1 synthetic 104 
lethal effect, that contributes to its translational value, is that it is highly 105 
penetrant2; i.e. in otherwise molecularly diverse pre-clinical models, and 106 
cancer patients, the presence of the predictive biomarker, in this case BRCA1 107 
or BRCA2 mutation, more often than not predicts a profound anti-tumour cell 108 
response to a PARP inhibitor. This highly penetrant nature suggests that this 109 
particular synthetic lethal effect is robust in the face of the molecular 110 
heterogeneity that exists between different human cancers. Here, we describe 111 
efforts to identify highly penetrant synthetic lethal effects associated with 112 
deleterious Rb alterations in TNBC; we reasoned that those with greatest 113 
penetrance will be more likely to operate in the diverse molecular contexts 114 
within the TNBC subtype and thus represent more promising therapeutic 115 
targets. Although genes such as TSC254 and elements of the Dicer pathway44 116 
have been shown to be synthetic lethal with Rb defects, as far as we are 117 
aware, the penetrance of these effects, or whether these operate in models of 118 
TNBC, has not as yet been assessed. The availability of several, large-scale, 119 
shRNA and siRNA screens8, 9, 42, 62, conducted in multiple tumour cell lines, 120 
some of which are derived from TNBCs, now make a detailed identification of 121 
highly penetrant RB1-related synthetic lethal effects now possible. For this 122 
reason, we describe here a detailed molecular analysis of Rb status in tumour 123 
cell lines derived from TNBC. We then designed a straightforward data 124 
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analysis pipeline that allowed us to use this Rb annotation to interrogate both 125 
in-house and publically available large-scale, shRNA and siRNA screens to 126 
identify candidate Rb-related synthetic lethal effects. Included within this data 127 
analysis pipeline, we included an estimate of penetrance. In triaging the 128 
candidate Rb-synthetic lethal effects that operated in TNBC tumour cells to 129 
identify those with greatest penetrance, we identified a series of 130 
pharmacologically tractable effects, one of which, SKP2, we validated using 131 
both genetic and pharmacological methods. We also noted that a significant 132 
proportion of the highly penetrant Rb SL effects in TNBC involved proteins 133 
closely associated with Rb function, suggesting that this might be a defining 134 
characteristic. 135 
 136 
Results 137 
Annotation of Rb status in TNBC tumour cell lines 138 
To identify highly robust synthetic lethal effects associated with Rb defects in 139 
TNBC, we classified a molecularly diverse panel of TNBC tumour cell lines 140 
(TCLs) according to Rb status and then used this Rb classification to 141 
interrogate publically available genetic screen data using a data analysis 142 
pipeline (described later) that identified highly penetrant synthetic lethal 143 
effects. To do this, we first classified TNBC tumour cell lines using a 144 
combination of genomic, transcriptomic and proteomic data to identify those 145 
with Rb genetic or epigenetic defects. We used western blotting to assess Rb 146 
protein expression in 30 breast TCLs, including 16 TNBC (Figure 1A,B). In 147 
this analysis, we found that TCLs with deleterious mutations in the RB1 gene 148 
(BT549, RB1 c.265_607del343, MDAMB468, RB1 c.265_2787del2523, 149 
DU4475, RB1 c.1_2787del2787, MDAMB436, RB1 c.607_608ins107) lacked 150 
Rb protein expression, suggesting that the mutational status of RB1 151 
correlated with protein expression (Figure 1A,B). We also found that SUM149 152 
cells exhibited low Rb protein expression, an observation we found to be 153 
consistent with reduced RB1 mRNA levels (Supplementary Data 1). To 154 
assess Rb protein status by orthogonal means, we compared our western blot 155 
data with publically available mass spectrometry data describing the 156 
proteomic profiles of 16 TNBC tumour cell lines33. Using average intensity-157 
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based absolute protein abundance (iBAQ) data for Rb from mass 158 
spectrometry profiling33 (Supplementary Data 1), we found that TNBC TCLs 159 
classified by western blotting as being Rb defective exhibited no Rb peptides 160 
(MDAMB468, MDAMB436, HCC1937, DU4475, BT549) when compared to 161 
those tumour cell lines we had classified as Rb proficient (Figure 1C, 162 
p=0.0002), giving us some confidence in our classification. Examination of 163 
transcriptomic profiles of TNBC TCLs3 revealed that TCLs with reduced levels 164 
of RB1 mRNA exhibited low Rb protein expression (Figure 1D, p=0.0075), 165 
suggesting that RB1 mRNA expression levels could be used as a reasonable 166 
proxy for protein expression. Taking proteomic, genomic and transcriptomic 167 
data into consideration (Figure 1E), we then classified a total of 42 TNBC 168 
TCLs according to Rb status, identifying 12 with one or more defects in Rb 169 
(“Rb defective” e.g. low protein expression, truncating mutation/gene deletion, 170 
reduced mRNA levels: BT549, HCC1937, DU4475, MDAMB436, MDAMB468, 171 
CAL148, HDQP1, MB157, SUM149, HCC1187, HCC3153 and CAL851) and 172 
30 TNBC TCLs as not exhibiting such defects (“Rb not altered” TCLs). 173 
 174 
To further assess the validity of our Rb classification, we assessed the 175 
transcriptomic profiles of Rb defective TNBC TCLs to assess whether these 176 
reflected loss of Rb function (Figure 1F). Using the Rb defective and Rb not 177 
altered classification described above for 42 TNBC TCLs, we identified 839 178 
differentially expressed genes (452 with reduced expression in Rb defective 179 
TCLs, 387 with elevated expression (p<0.05, Limma analysis, Supplementary 180 
Data 2)). As expected, we found RB1 itself to be the fifth most down-regulated 181 
gene in the Rb defective TCLs compared to Rb not altered TCLs (log fold 182 
change of -2.4, p value = 1.6x10-6 (Limma analysis); Supplementary Data 2 183 
and Figure 1F). We also found that Rb defective TCLs exhibited elevated 184 
expression of cyclins associated with G1 checkpoint control and S phase 185 
progression (Cyclin E1 (p=0.03), E2 (p=0.02), CDKN2A (p16; p=0.002)), as 186 
well as elevated expression of the Rb regulated E2F3 transcription factor and 187 
its binding partner TFDP1 (Figure 1F (p=0.005 and p=0.0001, respectively)). 188 
Using the ENRICHR annotation tool12 to identify pathways rather than 189 
individual genes that were differentially expressed in the Rb defective group, 190 
we found that pathways related to Rb and G1 to S cell cycle control to be 191 
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among the most significantly dysregulated in Rb defective TNBC TCLs, 192 
including “Retinoblastoma (RB) in Cancer WP2446” p=1.7 x 10-11 and “G1 to S 193 
cell cycle control WP45” p=1.4 x 10-9, both of which included genes such as 194 
MCM4,6 and 7, TFDP1, CCNE1, CCNE2, CHEK1, E2F3, and RBP1. Using 195 
the same annotation tool we also searched for the key transcription factors 196 
that regulated genes that were differentially expressed in Rb defective TNBC 197 
TCLs. We found that a significant proportion of the differentially expressed 198 
genes in Rb defective TNBC TCLs were targets of Rb-related E2F-family 199 
transcription factors including E2F7, E2F4 and E2F1 (e.g. p =0.001; 0.005; 200 
9.3 x 10-7 for E2F7; E2F4 and E2F1 respectively).  201 
 202 
To compare the observations made in TCLs with TNBC tumours, we used the 203 
same approach of exploiting RB1 gene mutation/copy number status and RB1 204 
mRNA expression profiles to classify 140 TCGA triple negative breast 205 
tumors10 according to Rb status; this approach identified 48 Rb defective 206 
TNBC tumours and 92 where Rb was not altered. Assessing the 207 
transcriptomic profiles of these TNBCs we again found that genes associated 208 
with Rb and Rb-related G1 to S cell cycle control were frequently dysregulated 209 
in Rb defective TNBCs including CDKN2A, TFDP1, CCNE1, CCNE2, E2F3, 210 
CHEK1 and DYRK1A, a recently identified RB1 synthetic lethal gene9 (Figure 211 
1G, Supplementary Data 3), consistent with the observations made in TNBC 212 
TCLs. We also applied the same approach to classify 182 Metabric TNBC 213 
tumours46 according to Rb status; this approach identified 55 Rb defective 214 
and 132 Rb not altered TNBC samples. Assessing the transcriptomic profiles 215 
of these TNBCs we again found that genes associated with Rb and Rb-216 
related G1 to S cell cycle control were frequently dysregulated in Rb defective 217 
TNBCs (Figure 1H, Supplementary Data 4). These global transcriptional 218 
patterns in Rb defective TNBC TCLs and human tumours suggested that our 219 
Rb classification approach was somewhat valid. 220 
 221 
  222 
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A pipeline for the identification of highly-penetrant Rb synthetic lethal 223 
effects in TNBC 224 
Using the Rb classification of TNBC TCLs described above, we re-analysed 225 
publically available genetic screen data (e.g. genome-wide shRNA screen 226 
data42, 62, gene subset shRNA screen data43 or gene subset siRNA data8, 9) 227 
from TNBC TCLs, using a series of iterative data processing steps designed 228 
to identify highly-penetrant synthetic lethal effects (Figure 2A). In summary, 229 
these steps involved: (i) step one – identification of candidate synthetic 230 
lethal effects: using shRNA screen data42 for 12 Rb defective TNBC cell 231 
lines and 30 Rb not altered cell lines we used the siMEM algorithm42 to 232 
identify those genes whose inhibition appeared to target the Rb defective 233 
models to a greater extent than Rb proficient TNBC TCLs (p<0.05). (ii) steps 234 
two and three – apply Z score thresholds to identify profound cell 235 
inhibitory effects: although step one allowed us to identify genes whose 236 
inhibition selectively targeted Rb defective TCLs to a greater extent than Rb 237 
not altered TCLs, we reasoned that the scale of cell inhibition in these two 238 
TCL cohorts might also be critical in identifying the most suitable therapeutic 239 
targets. For example, for the purposes of identifying novel therapeutic targets 240 
we were less interested in genes whose inhibition profoundly inhibited both 241 
Rb defective and Rb not altered groups, even if the Rb defective models 242 
exhibited significantly greater sensitivity; we assumed that inhibition of these 243 
targets would likely cause significant normal cell toxicity. Similarly, we also 244 
assumed that candidate synthetic lethal effects that did not elicit profound cell 245 
inhibitory effects in Rb defective TCLs would be less likely to elicit profound 246 
anti-cancer therapeutic effects when exploited clinically. For these reasons, 247 
we triaged the list of candidate synthetic lethal effects identified in step 1 to 248 
remove from further analysis: (a) those genes that appeared to be synthetic 249 
lethal with Rb but whose targeting elicited profound cell inhibition in Rb not 250 
altered TCLs; and (b) those genes that appeared to be synthetic lethal with 251 
Rb but whose targeting did not elicit profound cell inhibitory effects in Rb 252 
defective TCLs. To do this we used shRNA/siRNA Z score thresholds to 253 
estimate the effect of each RNAi reagent; (iii) steps four and five – identify 254 
effects with greatest penetrance: We reasoned that the most clinically 255 
effective synthetic lethal targets are likely to be those that have complete or 256 
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highly penetrant effects, i.e. the presence of the predictive biomarker (in this 257 
case an Rb defect) is more often than not associated with profound sensitivity 258 
to target inhibition. For this reason, we finally triaged synthetic lethal effects by 259 
calculating synthetic lethal penetrance scores; in this case, synthetic lethal 260 
penetrance (SLP) for each synthetic lethal effect was calculated as the 261 
percentage of Rb defective TCLs that exhibited a Z score of less than -1 when 262 
targeted with shRNA. We also calculated synthetic lethal coverage (SLC) 263 
scores, i.e. the percentage of TNBC TCLs that were sensitive to shRNA that 264 
were Rb defective, to estimate the specificity of synthetic lethal effects for Rb 265 
defects.  266 
 267 
To illustrate the concepts of penetrance and coverage as applied to functional 268 
genomic screens in tumour cell lines, we examined a well-characterised and 269 
therapeutically actionable oncogene addiction effect that operates in breast 270 
cancer, namely that associated with amplification of the epidermal growth 271 
factor receptor oncogene, ERBB2. Amplification and overexpression of 272 
ERBB2 is used clinically to stratify breast cancer patients for treatment with 273 
ERBB2-targeting agents such as the monoclonal antibody trastuzumab59. In 274 
examining the Colt2/Marcotte et al shRNA dataset (78,432 shRNAs targeting 275 
16,056 genes in 77 breast TCLs representing TNBC and non-TNBC 276 
subtypes42, we found that, as shown before42, that shRNA targeting of ERBB2 277 
selectively targeted ERBB2 amplified breast TCLs (siMEM, p<0.0001), elicited 278 
minimal inhibition in ERBB2 non-amplified TCLs (median Z -1), profound 279 
inhibition in ERBB2 amplified TCLs (median Z -3) and had a SLP 280 
(penetrance) score of 80% and a SLC (coverage) score of 28% (Figure 2B); 281 
the high penetrance score in this case, taken together with ERBB2 fulfilling 282 
the other selection criteria, reconfirms ERBB2 as a suitable therapeutic target 283 
in appropriately stratified breast cancer patients.  284 
  285 
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Identification of Rb synthetic lethal effects from shRNA screens 286 
To identify Rb synthetic lethal effects, we first used genome-wide shRNA data 287 
from 42 TNBC TCLs described in the Colt2/Marcotte et al study42. In this 288 
dataset, the combined effects of multiple shRNAs targeting a single gene are 289 
described as Z normalised Gene Activity Ranking Profile (zGARP) scores41. 290 
We re-analysed this shRNA screen data using the siMEM mixed effect linear 291 
model method (see step one, above), which identifies synthetic lethal effects 292 
by estimating the depletion or “drop-out” rate of individual shRNAs in cohorts 293 
of cell lines classified according to a molecular feature42, in this case Rb 294 
deficiency. Using the siMEM approach with our Rb classification of 42 TNBC 295 
TCLs, we identified 1065 Rb-specific dependencies (p<0.05, siMEM, Figure 296 
2C): 437 genes where shRNA preferentially inhibited Rb defective TNBC (i.e. 297 
Rb synthetic lethal effects) and 628 genes where shRNAs preferentially 298 
targeted Rb proficient TNBC TCLs (Supplementary Data 5). Amongst these, 299 
we noted that shRNAs targeting CDK4, CDK6 or the CDK4,6 cyclin partner 300 
gene Cyclin D1 (CCND1) preferentially inhibited Rb proficient TNBC TCLs 301 
(Figure 2C), consistent with the hypothesis that inhibition of CDK4,6 activity 302 
restores cell cycle control in Rb proficient TNBC tumour cells and elicits cell 303 
inhibition1. In terms of identifying Rb dependencies, we noted that the siMEM 304 
analysis of the Colt2 dataset identified shRNA targeting the E2F family 305 
transcription factor, E2F3, as being one of the most significant Rb synthetic 306 
lethal effects (Figure 2C). These Rb-related observations thus gave us some 307 
confidence in the approach. We also carried out similar analyses in 308 
siRNA/shRNA datasets that included TNBC TCLs, from other sources: the 309 
DRIVE dataset43, the Achilles dataset62 and the ICR-Intercell dataset8, 9 and 310 
provide the lists of Rb dependencies identified in these datasets in 311 
Supplementary Data 6, 7, 8, respectively.   312 
 313 
  314 
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Application of Z score thresholds identifies profound cell inhibitory 315 
effects 316 
As described above, we were interested in identifying Rb synthetic lethal 317 
effects that had profound effects in Rb defective TNBCs but had minimal 318 
effects in cells without Rb defects. Although approaches such as siMEM are 319 
useful in identifying putative vulnerabilities, they often do not, when used in 320 
isolation, identify synthetic lethal effects with these favoured characteristics. 321 
For example, Figure 2D and 2E illustrate a pair of p<0.05 Rb dependencies 322 
identified by siMEM analysis (Step One), that had either profound cell 323 
inhibitory effects in both Rb not altered as well as Rb defective TNBC TCLs 324 
e.g. PSMD1 (Figure 2D, siMEM p = 3 x 10-5, median Z in Rb defective of -6, 325 
median Z in Rb not altered of -4) or relative paucity of profound cell inhibition 326 
effects in the Rb defective TCL cohort, e.g. KLF16 (Figure 2E, siMEM p = 327 
0.0002, median Z in Rb defective of -0.8). To eliminate such effects from 328 
further study, we applied a pragmatic approach that removed from further 329 
assessment p<0.05 synthetic lethal effects where the median zGARP score in 330 
the Rb defective TCLs was >-1 (i.e. effects where profound cell inhibition in 331 
Rb TCLs not observed) and those effects where median zGARP score in Rb 332 
proficient effects was <-2 (i.e. dependencies which still elicited profound cell 333 
inhibition in Rb proficient TCLs); three examples that fulfilled these criteria, 334 
GPS1, SNRPF and SNW1, are shown in Figure 2F,G,H. This triage step 335 
identified 122 Rb synthetic lethal effects in the Colt2 dataset that fulfilled these 336 
criteria (Supplementary Data 9). Similarly, triaged dependencies were 337 
identified in the DRIVE43, Achilles62 and ICR-Intercell datasets8, 9 338 
(Supplementary Data 10, 11 and 12, respectively).  339 
 340 
Highly penetrant Rb synthetic lethal effects in TNBC include TAF1, TAF1 341 
target genes, nuclear pore complex proteins and the SCFSKP-COP9 342 
signalosome complexes  343 
We next calculated synthetic lethal penetrance (SLP) and coverage (SLC) 344 
scores for each Rb synthetic lethal effect triaged in steps two and three. In our 345 
analysis of the Colt2 dataset, we calculated SLP and SLC scores for 122 Rb 346 
synthetic lethal effects, identifying 54 effects that had greater than 80 % 347 
penetrance (Figure 3A (SLP>90% shown), Supplementary Data 9) and also 348 
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identified highly penetrant effects from our analysis of the DRIVE and Achilles 349 
and ICR-Intercell datasets (Supplementary Data 10, 11 and 12, respectively). 350 
Amongst the highly penetrant Rb SL candidates (>80% penetrant), a 351 
significant number are known to be involved in RNA splicing (Supplementary 352 
Figure 1, p=5.14x10-12, GO Biological Processes 2017, “mRNA splicing, via 353 
spliceosome”, Enrichr12, Supplementary Data 13), including: ISY1 (SLP = 354 
92%); SON (SLP = 100%); CWC22 (SLP = 100%); DDX23 (SLP = 100%); 355 
POLR2E (SLP = 100%); GEMIN5 (SLP = 92%); POLR2F (SLP = 100%); 356 
TFIP11 (SLP = 92%); SRRM2 (SLP = 83%); LSM2 (SLP = 83%); SNW1 (SLP 357 
= 83%); SART3 (SLP = 83%); FIP1L1 (SLP = 83%) and SNRPD3 (SLP = 92). 358 
Interestingly, a RNAi screen in C.elegans also identified a synthetic lethal 359 
interaction between Rb loss and components of the splicing machinery11. 360 
Similarly, a number of proteins involved in the regulation of translation were 361 
also identified as candidate Rb SL targets (p=1.7x10-7, GO Biological 362 
Processes 2017, “regulation of translation by machinery localisation”, 363 
Enrichr12, Supplementary Figure 1, Supplementary Data 13). These included: 364 
RPS24 (SLP = 83%); RPS27 (SLP = 100%); RPS28 (SLP = 100%); RPL18A 365 
(SLP = 92%); RPL13A (SLP = 92%); RPL10 (SLP = 92%); TCOF1 (SLP = 366 
92%); GEMIN5 (SLP = 92%) and RPL38 (SLP = 92%).  367 
 368 
We also identified two nuclear pore complex (NPC) components4, 22, NUP88 369 
(SLP = 100%) and NUP214 (SLP = 83%) as highly penetrant Rb synthetic 370 
lethal partners (Supplementary Figure 1, Supplementary Data 13). NPCs are 371 
responsible for trafficking proteins between the nucleus and the cytoplasm. In 372 
particular, NPCs control spindle assembly, faithful chromosome segregation 373 
and mitotic progression by controlling the temporal and spatial localisation of 374 
proteins6, 45, 66 including the E2F transcriptional target and spindle assembly 375 
checkpoint (SAC) protein, MAD2, whose elevated expression is required for 376 
chromosomal instability in Rb defective cells50, 52. It seems possible that the 377 
highly penetrant synthetic lethalities between Rb and NUP88 or NUP214 378 
could be related to the temporal and spatial localisation of MAD2, perhaps by 379 
causing a level of excessive genomic instability that is incompatible with cell 380 
viability. 381 
 382 
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When taking all of the highly penetrant Rb synthetic lethal effects identified in 383 
the analysis of the Colt2 dataset into account, a significant number of these 384 
included genes/proteins known to be associated with Rb function including the 385 
Rb interacting protein TAF1 (siMEM p=0.016, SLP 92% and SLC 38%, Figure 386 
4A)56. TAF1 encodes the major 250 kDa subunit of the transcription initiation 387 
factor, TFIID57 which binds core promoter regions, including promoter start 388 
sites in genes implicated in cell cycle control36. We found that over half (n = 389 
33) of the highly penetrant Rb synthetic lethal genes encompassed putative 390 
TAF1 binding sites, as defined by TAF1 Chip-Seq data12, 16 a significant 391 
enrichment over chance alone (p = 2.72 x10-13, Figure 4B). One mechanistic 392 
explanation for these observations might be that many of the highly penetrant 393 
Rb synthetic lethal interactions that operate in TNBC are caused by aberrant 394 
TAF1 activity, a downstream effect of Rb dysfunction. TAF1 encompasses 395 
two protein domains, a kinase and bromodomain, which in principle are 396 
pharmacologically tractable. When taken together with the highly penetrant 397 
Rb synthetic lethal interaction, this might make TAF1 an attractive target for 398 
cancer drug discovery7, 18, 53.  399 
 400 
SKP1 and SKP2 were also identified as highly penetrant Rb synthetic lethal 401 
effects (Figure 4C,D, SLP 100% and 92% for SKP1 and SKP2, respectively). 402 
Both SKP1 and SKP2 are part of an E3 ubiquitin ligase complex, SCFSKP2 403 
(Skp, Cullin F-box containing complex), whose activity is greatest during late 404 
G1/early S phase of the cell cycle. Using ubiquitin ligation, the SCF
SKP2 
405 
complex targets proteins for proteasomal degradation including the cyclin 406 
dependent kinase inhibitors, p21 and p2767. Three other highly penetrant Rb 407 
synthetic lethal effects identified were also associated with the SCF complex 408 
(Figure 4E-G); COPS1 (aka GPS1, SLP 83%, Figure 4E), COPS3 (SLP 83%, 409 
Figure 4F) and COPS4 (SLP 92%, Figure 4G) encode components of the 410 
COP9 (Constitutive photomorphogenesis 9) signalosome complex (CSN35, 37). 411 
CSN regulates the ubiquitin ligase activity of SCF complexes via the 412 
deneddylation of the ring finger subunits (e.g. Rbx1) within SCF15  (Figure 4I). 413 
We also noted that CKS1B (CDC28 protein kinase regulatory subunit 1B) also 414 
represented a penetrant Rb synthetic lethal partner (SLP 58%, Figure 4H); 415 
together with its co-factor SKP2, CKS1B provides the substrate specific 416 
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targeting of p27 by SCFSKP2 47. When we compared transcriptomic data from 417 
RB1 defective TNBCs to those from TNBC with no apparent RB1 defect 418 
(Supplementary Data 3 and 4), we noted that RB1 defective TNBCs 419 
expressed significantly elevated levels of SKP2 and COPS1 (GPS1) mRNA 420 
(Figure 4J,K,L, p<0.05 for both TCGA10 and Metabric46 data, Wilcox rank sum 421 
test), suggesting that in these particular tumours, elevated SKP2 activity might 422 
buffer the effects of RB1 dysfunction. 423 
 424 
SKP2 directly interacts with Rb28 and has previously been shown to be 425 
required for the hyper-proliferative phenotype of Rb-depleted human 426 
retinoblastoma cells, via its regulatory control over p27 levels67. In cells with 427 
normal G1/S cell cycle control, Rb binds SKP2, impairing its activity within the 428 
SCFSKP2 complex; loss of Rb however, results in elevated SKP2 activity, a 429 
resultant reduction in p27 and p21 protein levels, loss of Cyclin E-CDK2 and 430 
Cyclin D-CDK4,6 inhibition and thus progression of cells through the G1 431 
restriction point and into S phase40. To directly test whether Rb loss in a 432 
breast epithelial cell could cause synthetic lethality with SKP2 inhibition, we 433 
silenced SKP2 using two different siRNAs in non-tumour breast epithelial 434 
MCF10A cells expressing either a shRNA silencing RB1 or a non-silencing 435 
(NS) control shRNA (Figure 5A). Silencing of SKP2 (Figure 5B) elicited 436 
synthetic lethality in Rb defective cells but not Rb proficient cells (Figure 5C, 437 
Student’s t test p<0.0001, Supplementary Figure 2). We also found that the 438 
toolbox SKP2 inhibitor SKPinC1, which impairs the binding of phosphorylated 439 
p27 to the substrate recognition pocket formed by SKP2 and CKS1B65, had a 440 
profound synthetic lethal effect on Rb defective MCF10A cells, but minimal 441 
effects in Rb wild type cells (p<0.001 two-way ANOVA, Figure 5D) and 442 
induced apoptosis in Rb defective cells (Supplementary Figure 3). We also 443 
assessed SKPinC1 sensitivity in 13 TNBC TCLs, and found that Rb defective 444 
TCLs were more sensitive than TCLs with no apparent Rb defect (Figure 5E 445 
and p<0.0022, Student’s t test). In addition, we confirmed that exposure of 446 
MCF10A cells with SKPinC1 inhibitor led to a stabilization of p27 protein 447 
levels (Figure 5F). Targeting of p27 by siRNA also partially reversed the 448 
inhibitory effect of SKPinC1 (Supplementary Figure 4), suggesting that the 449 
effect of SKPinC1 was p27 dependent. Taken together, these observations 450 
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suggested that SKP2 small molecule inhibition, could in principle, elicit the 451 
highly penetrant Rb synthetic lethal effect seen in TNBC tumour cells with 452 
RNA interference reagents.  453 
 454 
We also assessed whether other highly penetrant synthetic lethal effects 455 
operated in the RB1 isogenic MCF10A system. Using an arrayed siRNA 456 
screen we tested all 54 genes that we identified as highly penetrant (> 80% 457 
penetrance) RB synthetic lethal effects in TNBC cell lines in the Colt2 study 458 
along with an additional four controls (e.g. E2F3) for a total of 58 genes. We 459 
found that over half of the identified dependencies (55%) were observed in 460 
the isogenic system (Supplementary Figure 5), including profound synthetic 461 
lethal effects associated with TIMELESS, PCDH1, PITRM1, E2F3, SMN2 and 462 
TCOF1. This suggests that these effects can be specifically associated with 463 
RB loss, and that they are not an artefact of either the shRNA library used in 464 
Colt2 or the pooled screening approach. It seemed possible that differences in 465 
the proliferative rate of RB1 defective vs. wild type MCF10A cells could 466 
account for the synthetic lethal effects observed. However, we found that the 467 
proliferative rate of RB1 defective and wild type MCF10A cells was similar 468 
(Supplementary Figure 6), suggesting this might not have a significant bearing 469 
on the synthetic lethal effects identified. Moreover, analysis of previously 470 
published doubling times for 17 TNBC cell lines identified no significant 471 
difference between RB1 defective and RB1 proficient models (Mann-Whitney 472 
U-test p=0.4)25.  473 
 474 
We also assessed which of the highly penetrant Rb synthetic lethal effects 475 
identified in our analysis of the Colt2 data were also identified as highly 476 
penetrant effects in the TNBC TCLs in two other shRNA screens: Achilles62 477 
and DRIVE43. Comparing the p<0.05 Rb penetrant synthetic lethal effects 478 
between the three datasets, we noted that SKP2 was one of two synthetic 479 
lethal effects identified in all three screens, the other effect being associated 480 
with SART3, the RNA splicing factor (Figure 6A-C, Supplementary Data 9, 10 481 
and 11). In each screen, SKP2/Rb synthetic lethality was highly penetrant with 482 
SLP scores of 92% (Colt2), 75% (Achilles) and 100% (DRIVE dataset, Figure 483 
6D-F). Whilst the TNBC TCLs described in these three datasets are partially 484 
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overlapping, the shRNA libraries used were independently designed and 485 
synthesised and the screens independently carried out. As such, identifying 486 
SKP2 as a highly penetrant Rb synthetic lethal effect in all three datasets 487 
suggested that this effect was somewhat independent of the shRNA reagents 488 
used.  489 
 490 
Rb/SKP2 synthetic lethality operates in tumour cells from lung and other 491 
cancer histologies  492 
Rb defects are relatively prevalent in TNBC, but are not unique to this cancer 493 
subtype and are also evident in in many tumour types including, for example, 494 
small-cell lung cancers, bladder carcinomas, osteosarcomas, glioblastomas, 495 
endometrial carcinomas and retinoblastomas14, 17, 23, 27, 55. To estimate 496 
whether the highly penetrant Rb/SKP2 synthetic lethality in TNBC extended to 497 
other cancer histologies, we re-analysed the results of two recent large-scale 498 
shRNA screens that encompass TCLs derived from non-breast cancer 499 
histologies. Project DRIVE includes 373 non-breast tumour cell lines with 500 
available Rb mutation and copy number status that were derived from 18 501 
different cancer histologies43. In an analysis of the DRIVE dataset that 502 
excluded the breast tumour cell lines, we found a significant association 503 
between RB1 mutation/deletion and sensitivity to SKP2 shRNA (Figure 7A,B; 504 
MP-test p<0.0001, SLP=75%). Of over 6,000 genes tested, only E2F3 (MP-505 
test p<0.0001) showed a stronger association with Rb status (Figure 7A).  506 
Similarly, project Achilles includes 467 non-breast tumour cell lines with 507 
available Rb mutation and copy number status, derived from 20 different 508 
cancer histologies62. In an analysis of the Achilles dataset that excluded the 509 
breast tumour cell lines, we also found a significant association between RB1 510 
mutation/deletion and sensitivity to SKP2 shRNA (Figure 7C,D; MP-test 511 
p<0.0001, SLP=74%). Of over 17,000 genes, SKP2 synthetic lethality was the 512 
second most significant effect associated with Rb loss, after CDK2 (MP-test 513 
p<0.0001) with E2F3 being the third most significant effect (Figure 7C). The 514 
elevated penetrance of the Rb/SKP2 synthetic lethal effect in tumour cell 515 
models other than those derived from breast cancer suggested that this 516 
genetic dependency might operate in multiple histologies. When we 517 
considered the specific cancer histology of tumour cell lines, rather than 518 
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analysing these en mass, we found in both the Achilles and DRIVE datasets 519 
the Rb/SKP2 synthetic lethality was detectable in tumour cell lines derived 520 
from lung cancers (p=0.026/SLP=71% and p=0.0008/SLP=73% for DRIVE 521 
and Achilles, respectively; Figure 7E,F). However, we do note that the 522 
relatively small number of Rb defective tumour cell lines from non-lung cancer 523 
histologies in these datasets might impair the ability to detect the Rb/SKP2 524 
synthetic lethality. For example, in both DRIVE and Achilles datsets, we noted 525 
that Rb defective tumour cell lines derived from prostate cancer, 526 
osteosarcoma, liver cancer and oesophageal cancer, exhibited sensitivity to 527 
SKP2 shRNA (Figure 7G). 528 
  529 
Discussion 530 
There is now a relatively long-standing history of using genetic concepts such 531 
as synthetic lethality to identify novel therapeutic targets for the treatment of 532 
cancer24. In part these efforts have been successful, with synthetic lethal 533 
treatments39 and drugs that exploit oncogene addiction effects now being 534 
approved for the treatment of the clinical disease38. However, despite these 535 
advances, one challenge to this approach has been in identifying highly 536 
penetrant synthetic lethal effects that associate with the presence of a 537 
molecular biomarker. Here we describe efforts to identify highly-penetrant 538 
synthetic lethal effects associated with loss of the tumour suppressor Rb in 539 
TNBC. Following the classification of 42 TNBC TCLs according to Rb status, 540 
we interrogated genome-scale and focussed gene set shRNA screening 541 
datasets, identified candidate synthetic lethal effects and then used stringent 542 
filters to triage from the list of candidate synthetic lethal effects those most 543 
likely to represent highly penetrant effects. This approach allowed us to 544 
identify a number of highly penetrant synthetic lethal effects, many of which 545 
are associated with known functions of Rb and/or associated with Rb 546 
interacting proteins. These included TAF1 and TAF1 target genes as well as 547 
members of the SCFSKP2 complex.  548 
 549 
We note that there are considerable caveats associated with the approach we 550 
have taken to identifying highly penetrant Rb-related synthetic lethal effects in 551 
TNBC and the interpretation of the data; understanding these caveats is 552 
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critical to the use of the information we provide in this work. Primary amongst 553 
these is that we have exclusively used data from in vitro genetic screens to 554 
identify synthetic lethal effects and assess their penetrance. It seems likely 555 
that some of the effects identified in our analysis only operate in the context of 556 
two-dimensional in vitro culture and are abrogated, and therefore appear less 557 
penetrant, in three dimensional and/or in vivo settings. Such a possibility thus 558 
provides the rationale for also assessing synthetic lethal effects, and 559 
assessing their penetrance, in in vivo models of cancer. Secondly, there is 560 
little way of effectively estimating the true false negative rate of our approach; 561 
it is entirely possible that we have not identified real, highly penetrant, Rb 562 
related synthetic lethal effects either because the RNA interference reagents 563 
used in genetic screens ineffectively inactive the genes they are designed to 564 
target or because some other form of gene/protein inactivation (e.g. catalytic 565 
inhibition of the target protein rather than gene silencing) is required to elicit a 566 
synthetic lethal effect. Nevertheless, the identification in multiple, 567 
independently-conducted, genetic screens of the highly penetrant Rb/SKP2 568 
synthetic lethal effect, and its recapitulation with a small molecule inhibitor, 569 
suggests that this highly penetrant synthetic lethality effect is unlikely to be a 570 
false positive. 571 
 572 
As well as targeting Rb defective TNBC, the potential for using SKP2 573 
inhibition in other cancer histologies associated with Rb defects is 574 
considerable. For example, the hyper-proliferative phenotype of Rb-depleted 575 
human retinoblastoma cells and mouse melanotrophs is dependent upon the 576 
SKP263, 67 and the SKP2/CKS1 pocket inhibitor, SKPinC1, inhibits Rb/p53 577 
defective mouse prostate tumour cell organoids68. Finally, large-scale shRNA 578 
screens in tumour cell lines from a variety of cancer histologies (and our 579 
analysis described in Figure 6) suggest that the dependency of Rb defective 580 
TCLs upon SKP2 might extend beyond models of TNBC. Whether the high 581 
penetrance of the Rb/SKP2 synthetic lethality seen in models of TNBC 582 
extends to each of these histologies remains to be seen, but our initial 583 
analysis in Figure 6 suggests that highly penetrant effects might also be 584 
apparent in lung cancer.   585 
 586 
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It might be interesting to speculate what characteristics might differentiate a 587 
highly penetrant synthetic lethal effect that operates in cancer from less 588 
penetrant effects; being able to understand the factors that distinguish one 589 
from the other might eventually allow highly penetrant synthetic lethal effects 590 
in cancer to be predicted from first principles, thus reducing the reliance upon 591 
large-scale genetic screens in multiple tumour cell lines to empirically 592 
establish penetrance. From our relatively unbiased analysis of genome-scale 593 
shRNA screens, it is perhaps striking that many of the highly penetrant Rb 594 
synthetic lethal effects we identified (e.g. SKP1, SKP2, CKS1B, COPS1, 595 
COPS2, COPS3) have two characteristics: (i) they are closely, rather than 596 
distally, involved in controlling an essential process in highly proliferating 597 
tumour cells, namely G1 cell cycle progression by Cyclin/CDK activity; and (ii) 598 
this process is also closely, rather than distally, controlled by the synthetic 599 
lethal partner, Rb. It seems reasonable to think that synthetic lethal 600 
interactions that control essential processes in cancer cells via small-world 601 
networks (i.e. those than contain a relatively small number of nodes between 602 
synthetic lethal partners and proteins involved in essential processes) might 603 
be less likely to be reversed, and therefore more likely highly penetrant, than 604 
synthetic lethal effects that control essential processes via distal molecular 605 
mechanisms that involve larger molecular networks with multiple intervening 606 
nodes. Whether this turns out to be a general principle or not remains to be 607 
seen but already others have started to establish that many synthetic lethal 608 
effects associated with tumour suppressor genes other than Rb can be 609 
classified into a defined, and relatively small number of classes, including 610 
those between paralogs and those between genes in the same molecular 611 
pathway62. This suggests that some of the principles that govern how 612 
synthetic lethal effects operate in tumour cells can indeed be established.  613 
 614 
Materials and methods 615 
 616 
Cell lines, compounds and siRNA 617 
All cell lines were obtained from the American Type Culture Collection (ATCC) 618 
and maintained according to the supplier’s instructions. Cell lines were 619 
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routinely STR typed and mycoplasma tested. Cell lines were grown and 620 
transfected with individual and SMARTpool siGENOME siRNA (Dharmacon) 621 
and transfected using RNAiMAX (Invitrogen) reagent as described in9. 622 
Transfection efficiency was monitored using positive control (siPLK1) and two 623 
different negative control siRNAs (siCON1 and siCON2; Dharmacon, 624 
catalogue numbers D-001210-01-20 and D-001206-14-20). SKPinC1 inhibitor 625 
was purchased from Tocris (no. 4817) and was solubilised as a 10 mM stock 626 
solution in DMSO.  627 
 628 
Western blot analysis 629 
Whole cell protein lysates were extracted from cells by lysis with NP250 buffer 630 
(20mM Tris pH 7.6, 1mM EDTA, 0.5% NP40, 235mM NaCl). In gene silencing 631 
experiments, cell were cultured for 48 hours after siRNA transfection, at which 632 
point lysates were generated. Following a 20 minute incubation at 40C, 633 
lysates were centrifuged and supernatents collected. Electrophoresis was 634 
performed using Novex precast Bis-Tris gels (Invitrogen) and gels were 635 
blotted onto nitrocellulose filters as described previously21. Blots were 636 
immunoblotted in 5% (w/v) milk at 4C overnight using the following primary 637 
antibodies: anti-Rb1 (1/1000 (v/v) dilution in 5 % (v/v) milk, New England 638 
Biolab, 9309), anti-p16 (1/1000, abcam), anti-SKP2 (1/1000, New England 639 
Biolab, 4358), anti-p27 (1/1000, New Engand Biolab, 2552), anti-tubulin 640 
(1/1000, abcam) and anti-actin (1/1000, Santa Cruz, sc-1616). After washing, 641 
blots were incubated 1 hour at room temperature with secondary antibodies 642 
(Li-COR) diluted 1/10,000 (v/v) in 5% (w/v) milk. Protein bands were 643 
visualised and quantified using the Odyssey FC imaging system and 644 
ImageStudio software (Li-COR). 645 
 646 
Tumour and cell line expression analysis 647 
Limma48 was performed to identify differentially expressed genes RB1 648 
defective vs. RB1 not altered tumour cell lines, using data from 42 and 3. A 649 
design matrix with the cell line RB1 classifications was created and a linear 650 
model was fitted to expression values of each gene. Next, an empirical Bayes 651 
method was used to obtain more precise gene-wise variability estimates 652 
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between the two groups. Differential expression between groups was 653 
represented as log fold change scores with associated p-values and adjusted 654 
p-values. Publically available cell line mRNA expression datasets used in this 655 
study include Marcotte42 and CCLE3, as indicated. 656 
 657 
For the analysis of TNBC tumours, mRNA expression, DNA copy number and 658 
somatic mutation profiles for TCGA tumours were downloaded from GDAC 659 
(https://gdac.broadinstitute.org/), release 2016_01_28. GISTIC v2 level 4 data 660 
were used for copy number analysis and log2 ratios were converted to 661 
genomic gains/amplifications, neutral and loss/deletion states using threshold 662 
of log2(3/2). Raw Metabric data files were downloaded from the European 663 
Genome-phenome Archive (EGA; study ID EGAS00000000083). The 664 
Metabric breast cancer dataset was pre-processed, summarised and quantile-665 
normalised from the raw expression files generated by Illumina BeadStudio (R 666 
packages: beadarray v2.4.2 and illuminaHuman v3.db_1.12.2). Probe to 667 
gene-level mapping was performed by keeping the most variable (standard 668 
deviation) probe. Metabric copy number calls were used as published in the 669 
original study19. 670 
 671 
For TCGA breast cancer cohort, previously published34 TNBC6 and TNBC4 672 
calls were used resulting in 140 patients with matched mRNA, copy number 673 
and mutation profiles. For the Metabric cohort, TNBC6 calls were successfully 674 
derived from TNBC subtyping portal13 (http://cbc.mc.vanderbilt.edu/tnbc) for 675 
187 patients with matched mRNA and copy number profiles. In the TCGA 676 
cohort, TNBC samples with RB1 mRNA z-score < -1 were regarded as Rb-677 
low, RB1 copy number log2 ratio < -0.585 were regarded as Rb loss and 678 
samples with RB1 truncating mutations were considered as Rb inactivated. 679 
This resulted in 48 Rb defective and 92 Rb not altered TNBC samples. In the 680 
Metabric cohort, samples with RB1 mRNA z-score < -1 were regarded as Rb 681 
low, whilst samples with RB1 loss/deletions were regarded as Rb loss. This 682 
resulted in 55 Rb defective and 132 Rb not altered TNBC samples. 683 
 684 
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Differential gene expression analysis on TCGA TNBC samples was 685 
performed using Limma voom48. 686 
 687 
Association Testing 688 
The si/shRNA Mixed Effect Model (siMEM) was used to measure the 689 
essentiality of genes in the Colt2 genome-wide shRNA dropout screen42. 690 
siMEM uses hierarchical linear regression and considers level of each shRNA 691 
to be a regression function of its initial abundance over time, baseline trend in 692 
abundance over time and difference in abundance trend between samples 693 
sharing a common feature. siMEM results are represented as the difference 694 
between the dropout rate of hairpins in the two cell line groups being 695 
compared.  696 
For analysis of the DRIVE and Achilles shRNA screen datasets, where only a 697 
single screen time-point was collected, a one-sided median permutation (MP) 698 
test was used to identify associations between RB1 status of cell lines and 699 
their sensitivities to shRNA targeting of genes. For each gene, the observed 700 
difference between the median of scores of RB1 defective and RB1 not 701 
altered groups of tumour cell lines was compared. A total of one million 702 
random samples with the same sample size as in the two groups were 703 
created. The differences in the medians of the groups were calculated for 704 
each random sample and the statistical significance of the difference was 705 
determined. 706 
Cell viability assays 707 
500 cells per well were seeded into 384-well plates. After 24 hours cells were 708 
exposed to increasing concentrations of SKPinC1 inhibitor diluted in DMSO 709 
using an Echo 550 liquid handler (Labcyte). Cells were incubated with the 710 
inhibitor for five days after which cell viability was estimated with CellTitre-Glo 711 
reagent (Promega). For gene silencing experiments cells were incubated for 712 
five days following siRNA transfection prior to viability assessment. 713 
Luminescence readings from drug exposed cells were normalised to those 714 
from DMSO exposed cells to calculate Surviving Fractions (SF). SFs were 715 
used to derive four parameter logistic regression dose/response curves using 716 
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Graphpad Prism software, as per the manufacturer’s instructions. Apoptosis 717 
was measure using Caspase-Glo 3/7 reagent (Promega). 718 
 719 
Statistical analysis 720 
Unless otherwise stated all data is represented here as mean  standard error 721 
using Graphpad Prism Software (La Jolla, CA). All conditions were performed 722 
in triplicate in at least triplicate experiments. Statistical significance was 723 
measured using either Student’s t-test, pearson coefficient correlation, Mann-724 
Whitney U test or two-way ANOVA. p<0.05 was considered significant. 725 
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Figure and Table legends   1024 
Figure 1. Rb status in TNBC tumour cell lines. A. Western blot illustrating 1025 
Rb and p16 protein expression in 30 breast tumour cell lines (TCLs). BT549, 1026 
MDAMB436, MDAMB468 and DU4475 each possess loss of function 1027 
mutations in the RB1 gene. SUM149 cells express reduced RB1 mRNA. B. 1028 
Scatter plot illustrating quantification of Rb protein levels delineated from (A). 1029 
Protein expression in Rb defective vs. not altered, p=0.0484, Student’s t test. 1030 
C. Scatter plot illustrating Rb protein expression in defective and proficient 1031 
TNBC TCLs estimated by mass spectrometry data from33. TNBC TCLs were 1032 
classified into “Rb defective” and “not altered” groups according to western 1033 
blot data from (A); using this classification, normalised iBAQ Rb peptide 1034 
scores were compared and are shown. p=0.0002, Fishers exact test. D. 1035 
Scatter plot illustrating the correlation between Rb protein and mRNA 1036 
transcript levels in TNBC TCLs. Rb protein levels from (A,B) are compared to 1037 
Rb mRNA transcript levels obtained from the CCLE database3. Correlation 1038 
r=0.7, p=0.0075, Pearson’s correlation. E. Oncoprint illustrating Rb and breast 1039 
cancer subtype status amongst 42 TNBC TCLs. F. Volcano plot illustrating 1040 
mRNAs that are differentially expressed (limma analysis p<0.05) in Rb 1041 
defective (vs. Rb not altered) TNBC TCLs. Genes functionally related to Rb 1042 
are highlighted, as is Rb itself. G. Volcano plot of mRNAs that are differentially 1043 
expressed (limma analysis p<0.05) in 48 Rb defective (vs. Rb not altered) 1044 
triple negative breast tumours from the TCGA study10. Genes functionally 1045 
related to Rb are highlighted, as is Rb itself. H. Volcano plot of mRNAs that 1046 
are differentially expressed (limma analysis p<0.05) in 55 Rb defective (vs. Rb 1047 
not altered) triple negative breast tumours from the Metabric study46. Genes 1048 
functionally related to Rb are highlighted, as is Rb itself. 1049 
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Figure 2. Identifying highly penetrant Rb synthetic lethal effects that 1053 
operate in TNBC. A. Schematic illustrating the data analysis workflow used. 1054 
In the first instance, 16,056 gene zGARP scores from shRNA screens in 42 1055 
TNBC cell lines described in the Colt2 dataset were analysed; parallel 1056 
analyses were carried out using data from the DRIVE and Achilles datasets 1057 
(see main text). B. Scatter plot illustrating ERBB2 Z GARP scores in 77 breast 1058 
tumour cell lines partitioned according to effects in ERBB2 amplified and non-1059 
amplified TCLs. ERBB2 shRNA elicits a p<0.0001 oncogene addiction effect 1060 
(siMEM) with 80% penetrance in ERBB2 amplified tumour cell lines (red). 1061 
Coverage is also shown. C. Scatter plot illustrating 1065 p<0.05 significant 1062 
siMEM Rb synthetic lethal effects identified from the siMEM analysis of TNBC 1063 
TCLs in the Colt2 study (step one in (A)). p<0.05 effects are ranked ordered 1064 
by siMEM p value. E2F3 (synthetic lethal in Rb defective), CDK6, CDK4 and 1065 
the CDK4,6 cyclin partner, Cyclin D1 (CCND1) (dependencies in Rb not 1066 
altered) are highlighted. D,E. Scatter plots illustrating Z scores in 42 TNBC 1067 
TCLs for two siMEM p<0.05 candidate Rb synthetic lethal effects, PSMD1 (D) 1068 
and KLF16 (E), removed from further analysis by the use of Z score filters 1069 
(step two and three in (A)). zGARP scores for PSMD1 (preferentially target Rb 1070 
defective, siMEM p value 3 x 10-5) indicate all but two Rb not altered tumour 1071 
cell lines exhibit Z score of <-2 (median Z in not altered group < -4). zGARP 1072 
scores for KLF16 (preferentially target Rb defective, siMEM p value 0.0002) 1073 
indicate that the majority of Rb defective TCLs exhibit Z score of >-1 (median 1074 
Z in defective group = -0.8), despite median Z scores being significantly 1075 
different in Rb not altered vs. deficient TCLs. F-H. Scatter plots illustrating Z 1076 
scores in 42 TNBC TCLs for three siMEM p<0.05 candidate Rb synthetic 1077 
lethal effects, GPS1, SNRPF and SNW1 where median Z in defective group 1078 
<-1 and median Z in proficient group >-2 (step two and three in (A)). 1079 
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Figure 3. Highly penetrant Rb synthetic lethal effects. Scatter plots 1082 
illustrating Z scores in 42 TNBC TCLs for 30 candidate Rb synthetic lethal 1083 
effects which pass Z score threshold assessment and demonstrate a 1084 
penetrance score of greater than 90%, as summarised in steps 1-5 of Figure 1085 
2A.  1086 
 1087 
Figure 4. TAF1 and SKP2 as central nodes in highly-penetrant Rb 1088 
synthetic lethal networks. A. Scatter plot illustrating Z scores in 42 TNBC 1089 
TCLs for TAF1 from the data analysis illustrated in Figure 2A. B. Cytoscape 1090 
network plot illustrating 33 highly penetrant (>80% penetrance) Rb synthetic 1091 
lethal effects identified as TAF1 transcription factor target genes, as 1092 
annotated by ENCODE data12, 16. C-H. Scatter plots illustrating Z scores in 42 1093 
TNBC TCLs for SKP1, SKP2, COPS1,3,4 and CKS1B from the data analysis 1094 
in Figure 2A. I. Pathway diagram highlighting the role of multiple highly 1095 
penetrant Rb synthetic lethal effects in the control of p27 activity. J. Volcano 1096 
plot illustrating mRNAs from highly penetrant Rb SL genes that are 1097 
differentially expressed (limma analysis p<0.05) in 48 Rb defective vs. 92 Rb 1098 
not altered triple negative breast tumours from the TCGA study10. Four highly 1099 
SCFSKP/COP9 complex genes, highlighted in red, demonstrate significantly 1100 
higher mRNA expression levels in the Rb defective cell lines. K. As per panel 1101 
(J), using data from the Metabric study46 L. Box plots illustrating elevated 1102 
SKP2 or GPS1 (COPS1) mRNA expression in Rb defective TNBC from both 1103 
the TCGA 10 and Metabric studies46. p values shown calculated with Wilcox 1104 
rank sum test. 1105 
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Figure 5. Small molecule inhibition of SKP2 in Rb defective breast cell 1108 
lines is synthetic lethal. A. Western blot illustrating loss of Rb expression in 1109 
isogenic MCF10A non-tumour breast epithelial cells with constitutive 1110 
expression of either a control non-targeting shRNA (shCONTROL) or an Rb-1111 
targeting shRNA (shRB1). B. Western blot illustrating loss of SKP2 protein 1112 
expression in MCF10A cells 48 hours after transfection with SKP2 or control, 1113 
non-targeting, siRNAs (siCON1 or siCON2). C. Bar chart illustrating cell 1114 
inhibitory effects in isogenic MCF10A cells with/without stable expression of 1115 
Rb shRNA transfected with SKP2 siRNA. Cells were reverse transfected with 1116 
siRNAs as shown and cultured for five continuous days, at which point cell 1117 
viability was assessed by use of CellTitre Glo reagent. SKP2 siRNA caused 1118 
significant cell inhibition (p<0.001, Student’s t test) in cells with stable Rb 1119 
silencing, but not in cells with wild type Rb expression. D. Dose response 1120 
survival curves illustrating the cell inhibitory effects of the SKP2 small 1121 
molecule inhibitor, SKPinC1, in isogenic MCF10A cells with/without stable 1122 
expression of Rb shRNA. Cells were exposed to SKPinC1 for five continuous 1123 
days at which point cell viability was assessed by use of CellTitre Glo reagent. 1124 
Rb defective cells demonstrated a profound sensitivity, compared to Rb wild 1125 
type cells (p<0.0001, two-way ANOVA, SF50 = 1 M and >10 M in Rb 1126 
defective and wild type cells, respectively). E. Tumour cell inhibitory effect of 1127 
SKPinC1 in 13 TNBC TCLs classified according to Rb status. Cells were 1128 
exposed to 1 M SKPinC1 as in (H). Surviving fractions are shown (p=0.0022, 1129 
Student’s t test). F. Western blot illustrating p27 protein levels in Rb defective 1130 
cells exposed to 0.5 M and 1 M SKPinC1 for 24 hours.  1131 
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Figure 6. SKP2 identified as a highly-penetrant Rb synthetic lethal effect 1134 
in multiple, independently derived, datasets. A-C. Scatter plots comparing 1135 
p values (-log10) for Rb synthetic lethal effects identified in Colt2
42, Achilles62 1136 
and DRIVE43 datasets. p<0.05 effects in any single screen are shown. p<0.05 1137 
effects in two screens are shown the top right hand quadrant of each plot. 1138 
SKP2 and SART3, which were identified in all three screens as synthetically 1139 
lethal with Rb defects, are highlighted in red. p<0.05 effects in Colt2 data 1140 
were identified by siMEM, followed by Z score and penetrance filtering (see 1141 
Figure 2A); p<0.05 effects in DRIVE and Achilles data were identified by 1142 
median permutation t test, followed by Z score and penetrance filtering (see 1143 
Figure 2A) D. Scatter plots illustrating Z scores in 42 TNBC TCLs for SKP2 1144 
from the Colt2 data analysis. E. Scatter plots illustrating Z scores in 16 TNBC 1145 
TCLs for SKP2 from the Achilles data analysis. F. Scatter plots illustrating Z 1146 
scores in 12 TNBC TCLs for SKP2 from the Drive data analysis. 1147 
 1148 
Figure 7. SKP2 identified as a highly-penetrant Rb synthetic lethal effect 1149 
in other histologies in two independently derived datasets. A. Scatter plot 1150 
of 775 p<0.05 significant Rb synthetic lethal effects identified from the MP-test 1151 
analysis of 373 non-breast cancer TCLs in the Drive study (step one in Figure 1152 
1A). All 775 p<0.05 effects are ranked ordered by MP test p value. SKP2 and 1153 
E2F3 are highlighted. B. Scatter plot illustrating RSA scores in 373 non-breast 1154 
TCLs with Rb annotation for SKP2 sensitivity from the Drive data analysis. C. 1155 
Scatter plot of 1467 p<0.05 significant Rb synthetic lethal effects identified 1156 
from the MP-test analysis of 467 non-breast TCLs in the Achilles study (step 1157 
one in Figure 1A). All 1467 p<0.05 effects are ranked ordered by MP test p 1158 
value. SKP2 and E2F3 are highlighted. D. Scatter plots illustrating Demeter 1159 
scores in 1467 non-breast TCLs with Rb annotation for SKP2 sensitivity from 1160 
the Achilles data analysis. E,F. Scatter plots illustrating RSA and Demeter 1161 
scores in 63 and 115 lung TCLs with Rb annotation for SKP2 sensitivity from 1162 
the Drive and Achilles studies, respectively. G. Scatter plot of intersect of cell 1163 
line between the two datasets showing SKP2 sensitivity in Drive RSA scores 1164 
(x axis) and Achilles Demeter scores (y axis) for selected histologies with only 1165 
a single Rb defective line. This graph illustrates a trend between Rb defects 1166 
and sensitivity to SKP2 shRNA across seven different histotypes.  1167 
